IIFL Securities's Stock Idea: Buy Jubilant Ingrevia with Target Rs 592

On April 24, IIFL Securities recommended buying Jubilant Ingrevia with a target price of Rs 592, representing a potential upside of 2.93% from the current market price of Rs 577.05. This recommendation is based on the company's strong financial performance, growth opportunities in the specialty chemicals and pharmaceuticals sectors, and attractive valuations.

About Jubilant Ingrevia:

Jubilant Ingrevia Limited is a leading global integrated life sciences company with a diverse portfolio of businesses. Listed on the National Stock Exchange of India (NSE), the company operates in three primary segments: Life Science Ingredients, Specialty Pharmaceuticals, and Nutrition & Health. Jubilant Ingrevia's Life Science Ingredients business provides active pharmaceutical ingredients, excipients, and other ingredients to the pharmaceutical and healthcare industries. The Specialty Pharmaceuticals segment focuses on developing and commercializing proprietary branded and generic injectable pharmaceuticals. The Nutrition & Health business offers a range of nutritional ingredients and solutions to food, beverage, and supplement manufacturers.

52 Week Price Trend:

Jubilant Ingrevia, with a current market price of Rs 577.05, has exhibited a significant rise from its 52-week low of Rs 350.45. However, it still remains below its 52-week high of Rs 524.7. This indicates that the stock has room for further growth but also faces potential headwinds. Investors should carefully consider the company's fundamentals, market conditions, and industry outlook before making any investment decisions.

Stratzy's MOST Analysis:

Jubilant Ingrevia has received a MOST rating of BB- from Stratzy. The MOST framework evaluates companies based on their Management, Outlook, Safety, and Trend. A BB- rating indicates that the company has medium fundamental risks. This could be due to factors such as concerns about the company's management team, its financial outlook, its safety record, or its industry trends.

Company's Fundamentals:

Jubilant Ingrevia (NSE: JUBLINGREA) is a life science company with a stock PE ratio of 37.66, indicating that its share price is 37.66 times its annual earnings. Its PB ratio of 2.87 suggests that its share price is 2.87 times its book value, a measure of its assets minus liabilities. The company offers a dividend yield of 1.03%, implying it pays out 1.03% of its share price as dividends to shareholders annually. These metrics provide insights into the company's valuation, profitability, and income distribution policies.

Fundamental and Technical information provided in this blog were last updated on 24 Apr, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.